Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer

Part of paid clinical trials in Seattle, Washington.

Sponsor
University of Washington
Study ID
NCT07645651
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Borderline Resectable Pancreatic Ductal Adenocarcinoma
  • Locally Advanced Pancreatic Ductal Adenocarcinoma
  • Resectable Pancreatic Ductal Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Samuraciclib — DRUG
    Given PO
  • Computed Tomography — PROCEDURE
    Undergo CT
  • Endoscopic Ultrasound Biopsy — PROCEDURE
    Undergo EUS/FNB
  • Biospecimen Collection — PROCEDURE
    Undergo blood sample collection

Study Details

The purpose of this study is to evaluate the safety and efficacy of samuraciclib in patients with localized pancreatic cancer.

Key Dates

First listed
Jun 12, 2026
Start date
Sep 15, 2026
Status verified
Aug 2026
Primary completion
Jul 14, 2027
Completion
Nov 1, 2027

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (Samuraciclib)
    Patients receive samuraciclib PO QD for 14 days on study. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients will have a research EUS/FNB on study. Patients also undergo CT scans during screening and blood sample collection on study.

Primary Outcome Measure

Change in ribonucleic acid polymerase II serine levels [ Time Frame: Within 72 hours post versus pre-samuraciclib treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Fred Hutch/University of Washington Cancer ConsortiumSeattleWashington98109
Rachael Safyan, MD
[email protected]
206-606-2038
Isabel Blanco
[email protected]
206-606-5864
Rachael Safyan, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Seattle, WA

By research site
Fred Hutch/University of Washington Cancer Consortium· Seattle, WA

Related Studies